LON:AZN - AstraZeneca Stock Price, News, & Analysis

AstraZeneca trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

AstraZeneca announced a dividend on Thursday, February 14th. Investors of record on Thursday, February 28th will be paid a dividend of GBX 146.80 per share on Wednesday, March 27th. This represents a yield of 2.57%. The ex-dividend date of this dividend is Thursday, February 28th. This is a positive change from AstraZeneca's previous dividend of $68.40. The official announcement can be accessed at this link. View AstraZeneca's Dividend History.

AstraZeneca is scheduled to release their next quarterly earnings announcement on Thursday, July 25th 2019. View Earnings Estimates for AstraZeneca.

22 equities research analysts have issued 12-month target prices for AstraZeneca's shares. Their forecasts range from GBX 5,000 to GBX 8,500. On average, they anticipate AstraZeneca's share price to reach GBX 6,397.70 in the next twelve months. This suggests a possible upside of 8.9% from the stock's current price. View Analyst Price Targets for AstraZeneca.

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 3 sell ratings, 6 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AstraZeneca.

Media coverage about AZN stock has trended positive this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AstraZeneca earned a coverage optimism score of 2.2 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days.

Some companies that are related to AstraZeneca include GlaxoSmithKline (GSK), Bayer (BAYN), Dechra Pharmaceuticals (DPH), Hutchison China MediTech (HCM), Mayne Pharma Group (MYX), Vectura Group (VEC), Medical Developments International (MVP), Eco Animal Health Group (EAH), BEXIMCO PHARMAC/S GDR REGS (BXP), Opthea (OPT), Trilogy International Partners (TRL), Pharmaxis (PXS), Allergy Therapeutics (AGY), Vita Life Sciences (VLS) and Futura Medical (FUM).

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GlaxoSmithKline (GSK), Hain Celestial Group (HAIN), Vodafone Group (VOD), National Retail Properties (NNN), BP (BP), NVIDIA (NVDA), Marks and Spencer Group (MKS), British American Tobacco Plc Ads (BATS), Ford Motor (F) and Twitter (TWTR).

Shares of AZN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

One share of AZN stock can currently be purchased for approximately GBX 5,875.

AstraZeneca has a market capitalization of £77.07 billion and generates £22.40 billion in revenue each year. AstraZeneca employs 64,400 workers across the globe.

The official website for AstraZeneca is http://www.astrazeneca.com/.

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The biopharmaceutical company can be reached via phone at +44-20-73045000.